Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Frey

Showing results (321-330 of 368) with videos related to

Pageof 37
Sort By:
The Journal of Infectious Diseases|April 1, 2011
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteersPaul Spearman, Michelle A Lally, Marnie Elizaga, et al.
The Journal of Infectious Diseases|October 29, 2010
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissuesSamer S El-Kamary, Marcela F Pasetti, Paul M Mendelman, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
Vaccine|July 13, 2010
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsSharon E Frey, Michael Houghton, Stephen Coates, et al.
The Journal of Infectious Diseases|July 23, 2016
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster VaccinationDaniel F Hoft, Kathleen Lottenbach, Johannes B Goll, et al.
Vaccine|May 14, 2013
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenarioSharon E Frey, Patricia L Winokur, Robert A Salata, et al.
Genome Announcements|October 3, 2015
Draft Genome Sequence of Erwinia billingiae OSU19-1, Isolated from a Pear Tree CankerJeannie M Klein, Rhett W Bennett, Logan MacFarland, et al.
Vaccine|February 12, 2018
Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination seriesLea E Widdice, Rebecca Hoagland, S Todd Callahan, et al.
The Journal of Infectious Diseases|July 18, 2012
Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSharon E Frey, David I Bernstein, Michael A Gerber, et al.
Clinical and Vaccine Immunology : CVI|December 28, 2013
Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trialSerge Durviaux, John Treanor, Jiri Beran, et al.
Pageof 37

Showing results (321-330 of 368) with videos related to

Sort By:
Pageof 37
The Journal of Infectious Diseases|April 1, 2011
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteersPaul Spearman, Michelle A Lally, Marnie Elizaga, et al.
The Journal of Infectious Diseases|October 29, 2010
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissuesSamer S El-Kamary, Marcela F Pasetti, Paul M Mendelman, et al.
The Journal of Infectious Diseases|February 1, 1996
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation GroupG J Gorse, M C Keefer, R B Belshe, et al.
Vaccine|July 13, 2010
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adultsSharon E Frey, Michael Houghton, Stephen Coates, et al.
The Journal of Infectious Diseases|July 23, 2016
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster VaccinationDaniel F Hoft, Kathleen Lottenbach, Johannes B Goll, et al.
Vaccine|May 14, 2013
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenarioSharon E Frey, Patricia L Winokur, Robert A Salata, et al.
Genome Announcements|October 3, 2015
Draft Genome Sequence of Erwinia billingiae OSU19-1, Isolated from a Pear Tree CankerJeannie M Klein, Rhett W Bennett, Logan MacFarland, et al.
Vaccine|February 12, 2018
Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination seriesLea E Widdice, Rebecca Hoagland, S Todd Callahan, et al.
The Journal of Infectious Diseases|July 18, 2012
Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSharon E Frey, David I Bernstein, Michael A Gerber, et al.
Clinical and Vaccine Immunology : CVI|December 28, 2013
Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trialSerge Durviaux, John Treanor, Jiri Beran, et al.
Pageof 37